FDA Approves ThermoCool SmartTouch Dual‑Energy Ablation System

Johnson & Johnson’s ThermoCool SmartTouch platform has been updated to enable electrophysiologists to switch between radiofrequency and pulsed-field energy using a single catheter during heart ablation procedures. That combination of familiar catheter handling and a newer, non‑thermal ablation option is significant because it provides clinicians with a new tool for treating atrial fibrillation and other cardiac arrhythmias at a time when the field is rapidly adopting pulsed-field techniques.

Field of Electrophysiology

In electrophysiology, the landscape of catheter ablation has shifted significantly over the past few years. The rise of pulsed field ablation (PFA) has introduced a novel, tissue-selective therapeutic modality that stands alongside traditional, heat-driven radiofrequency (RF) ablation. Until recently, electrophysiologists were forced to choose their energy modality before starting a procedure, selecting entirely separate catheters, consoles, and clinical workflows. That paradigm has officially changed. The U.S. Food and Drug Administration (FDA) has approved the Johnson & Johnson Dual Energy THERMOCOOL SMARTTOUCH SF Platform (DE STSF). As an integrated catheter ablation solution, this new platform allows electrophysiologists to deliver both RF and pulsed field (PF) energy through a single catheter. For healthcare providers managing patients with atrial fibrillation (AFib) and complex arrhythmias, this regulatory milestone reshapes everyday practice.

Why It Matters

Catheter ablation is a cornerstone treatment for symptomatic atrial fibrillation. For decades, most operators have used thermal energy, typically radiofrequency (RF) heat, to create lesions that block rogue electrical circuits in the heart. More recently, pulsed field ablation (PFA) has emerged as a non‑thermal alternative that selectively disrupts cardiac muscle cells while sparing nearby structures. Combining RF and PFA in one system gives doctors more options mid‑procedure. That matters because patient anatomy and procedural goals vary. Having both energies available without changing catheters can shorten procedure time and reduce the need to convert to a different device.

Clinical Versatility Meets Tissue Selectivity

The FDA approval of the Dual Energy THERMOCOOL SMARTTOUCH SF Platform matters because it introduces unprecedented procedural flexibility into the electrophysiology (EP) lab.Rather than forcing a binary pre-procedural choice between two disparate technologies, this dual-energy platform allows physicians to adapt in real time.

The new dual‑energy ThermoCool SmartTouch platform is not just a gadget. It plugs into the clinical workflows and mapping systems many centers already use, so it may be easier to adopt than a wholly new device. That lowers the real barriers to uptake, including training and the learning curve. Broadly speaking, this approval signals that manufacturers and regulators see value in hybrid approaches: the field is moving from a single‑energy era to one where energy choice is part of procedural strategy. The result could be more individualized care, but it also raises questions about training, reimbursement, and how to measure long‑term outcomes.

Integration of different modalities

The integration of both modalities offers distinct clinical advantages.Traditional RF ablation uses thermal energy to create focal lesions, a highly effective technique with extensive long-term data, but one that carries a small risk of collateral thermal injury to adjacent structures like the esophagus or phrenic nerve.PFA utilizes short, high-voltage electrical pulses to create microscopic pores in cell membranes (irreversible electroporation).Because cardiac cells have a lower electroporation threshold than neighboring tissues, PFA provides a safety advantage by sparing vulnerable non-cardiac structures.

By housing both energy types in a single catheter, the DE STSF platform gives electrophysiologists the clinical versatility to choose RF or PF energy dynamically based on patient anatomy and changing case complexity.

Who It Affects

Better Workflows for Clinicians, Safer Routes for Patients

This technological integration directly impacts three primary stakeholders in the healthcare ecosystem:

• Patients
• Electrophysiologists and Clinical Teams
• Hospital Operations and Supply Chain Managers

Patients

Patients with symptomatic, drug‑refractory atrial fibrillation are the most obvious group impacted. For those referred for ablation, the availability of RF and pulsed-field energy may influence which center or operator they choose when outcomes, safety profile, and procedural efficiency are important considerations. Clinicians who perform ablations will need to gain practical experience with pulsed-field techniques if they do not already have it. That includes electrophysiologists, catheterization lab teams, and anesthesia and echo staff who support the procedure.

Electrophysiologists (EPs) and Clinical Teams

EPs face high spatial complexity when mapping and ablating arrhythmogenic substrates. As noted by Dr. Dhanunjaya Lakkireddy, Executive Medical Director at The Kansas City Heart Rhythm Institute, electrophysiologists require technologies that support varied anatomies and treatment goals. The DE STSF platform provides immediate relief from procedural rigidity, allowing clinicians to adapt their approach mid-procedure for complex substrates with greater confidence.

Hospital Operations and Supply Chain Managers

Hospitals and health systems will face decisions about capital equipment, training investments, and the incorporation of dual‑energy workflows into scheduling. Payers will want to know whether dual‑energy use yields better outcomes or lower overall costs through fewer complications and repeat procedures. Regulators and hospital credentialing committees will need to decide whether to require supervised proctoring for PFA use or simply allow credentialing based on experience with existing RF platforms. The new device’s integration with widely used mapping tools may ease some implementation hurdles, but it will not eliminate the operational planning required to bring a new platform into routine use.

Transitioning an EP lab to accommodate entirely separate PFA hardware typically entails substantial capital expenditures, inventory complexity, and staff retraining. Because this dual-energy catheter integrates natively with J&J’s existing CARTO mapping ecosystem, hospital systems can offer cutting-edge PFA technology without tearing down established infrastructure.

What Changes

• Clinicians can deliver both radiofrequency (RF) and pulsed field ablation (PFA) through the same catheter, enabling on‑the‑fly strategy changes without device swaps. This reduces procedural complexity in certain scenarios and broadens the treatment strategy.
• The platform is designed to work with existing three‑dimensional mapping systems and imaging tools many electrophysiology labs already use. That should lower the barrier to adoption and speed early cases at experienced centers.
• Hospitals and clinicians will have to invest in training and develop local guidance on when to use RF versus PFA, how to combine them safely, and how to document energy choices for reimbursement and quality monitoring. Payers and health systems may demand real‑world evidence showing comparative benefits before broadly supporting premium payments.
• Competition and choice in the marketplace are growing. Other device makers have PFA and dual‑energy programs in development or on the market, which will create options but also potential fragmentation in standards and training across centers. Clinicians will need to weigh device familiarity against specific energy features and evidence when selecting platforms.

Clinical Appropriateness

What this will not immediately change is the fundamental clinical judgment that determines whether a patient is a good candidate for ablation. Energy choice is one piece of a broader decision that includes symptom burden, heart structure, comorbid conditions, and patient preference. For complex or redo cases, hybrid approaches may offer advantages. For routine, straightforward pulmonary vein isolation, operators will have to assess whether PFA, RF, or a mix actually improves outcomes in their hands. That assessment will be local and pragmatic.

Trade-Offs

There are also safety trade‑offs to consider. Pulsed field ablation has been promoted for its tissue selectivity, which could reduce collateral injury to vulnerable structures such as the esophagus and phrenic nerve. But the technology is newer, and long‑term arrhythmia control compared with established RF approaches is still being defined in real‑world practice. Implementing dual‑energy approaches responsibly will require careful procedural protocols and post‑market data collection.

Operationally, a device that supports both energy modalities can simplify inventory management and reduce catheter exchanges. That matters in busy labs where every minute counts. It also means electrophysiology teams must coordinate device settings, mapping indices, and documentation to ensure consistency and safety. Manufacturers will be under pressure to provide robust training, proctorship, and digital tools to help centers capture procedural data and outcomes.

Policy and Payment

From a policy and payment perspective, the case is similar to other disruptive medical technologies. Early adopters will likely be high‑volume academic and referral centers that can absorb training costs and collect outcomes data. Payers and hospital systems will watch for signals that dual‑energy use reduces complications, shortens hospital stays, or lowers the need for repeat procedures. If those benefits appear in registries and real‑world studies, broader coverage and faster diffusion will follow. If not, uptake may be incremental and concentrated in specialized centers.

Looking Ahead

Looking ahead, the arrival of a commercially approved dual‑energy ThermoCool SmartTouch platform helps set a new baseline for what electrophysiology labs can expect from ablation technology. Competition from other major device makers advancing PFA and dual‑energy products will accelerate innovation and likely spur a swirl of comparative studies, registries, and practice guidance. For clinicians, the practical question is less about which energy is intrinsically superior and more about how to match tools, training, and patient selection to deliver reliable, reproducible outcomes.

Innovation

For patients, the message is straightforward. Innovations like this expand the options available during ablation and may reduce some risks associated with older thermal techniques. But outcomes depend on operator experience and the systems in which care is delivered. Patients should ask their electrophysiology teams how new technologies will affect their procedure, what the operator’s experience is with both RF and PFA, and how complications and follow‑up are handled locally.

Notable Milestone

In short, FDA authorization of a dual‑energy ThermoCool SmartTouch platform is a notable milestone. It reflects the field’s broader shift toward energy flexibility and personalization in catheter ablation. The technology itself promises practical advantages by marrying a familiar catheter platform with pulsed field capability. The real test will be how hospitals, clinicians, and payers incorporate the tool into everyday practice and whether real‑world use translates into consistently better patient outcomes.

References

1. Johnson & Johnson. Johnson & Johnson announces FDA approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform. July 8, 2026. Accessed July 13, 2026. https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-FDA-approval-for-the-Dual-Energy-Thermocool-Smarttouch-SF-platform
2. MassDevice. Johnson & Johnson FDA approval Thermocool Smarttouch DE. July 2026. Accessed July 13, 2026. https://www.massdevice.com/johnson-johnson-fda-approval-thermocool-smarttouch-de/